louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03032003: Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women
Official title: Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women: A Randomized, Comparative, Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Recurrent Urinary Tract Infections in Women
Lead sponsor: University of Thessaly
Sponsor class: OTHER
First posted: 2017-01-26
Enrollment: 160
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate if oral administration of 240mg PAC of cranberries can reduce the number of episodes of acute bacterial cystitis and improve general QoL in women with recurrent bacterial cystitis. In addition, the effect on vagina and rectal flora will studied and the adverse effect profile of the drug will be reported.

Women with ≥3 symptomatic episodes of lower UTIs at the previous year will be recruited from the outpatient population who present to their family physician or specialist with symptomatic recurrent UTI. Informed consent will be obtained from all patients and they will be divided in groups according to their age. Urinary culture, vaginal and rectal swab will be taken from all the patients. Antibiotic treatment will be prescribed (using the drug of choice according to the urine culture and the treating physician choice). Subsequently, they will be randomized to receive combined antibiotic treatment with one capsule of Cysticlean 240mg PAC two times per day or antibiotic treatment with placebo. At 14th day post treatment and after a negative urinary culture patients will continue to receive per os, daily, one capsule of Cysticlean 240mg at bed time for 12 months or placebo respectively.

Study visits will occur at 3rd, 6th , 9th and 12th month treatment phase. A urine collection, vaginal swabs and rectal swab will be taken at study entry and at the month 3, 6, 9 and 12 visits.

Participants will be asked about medication usage, any side effects they may be experiencing at each study visit. If participants develop a UTI at any time during the study, they will be asked to visit the study site within 24 hours.


Eligibility criteria: Inclusion Criteria:

* Negative urine culture
* At least 3 UTI's within 12 months prior to study entry

Exclusion Criteria:

* Anatomic abnormalities of the urinary tract
* Use of investigational drugs within 30 days prior to study entry
* Current use of warfarin
* Allergy or intolerance of cranberry products
* \> 50 ml of residual urine (measured by US)
* Use of indwelling catheter
* uncontrolled diabetes
* creatinine \> 250 mmol/l,
* Symptomatic vaginitis
* Pregnant or breastfeeding

Primary outcomes:
measure: Effectiveness of the use of Cranberries in the prevention of the recurrent UTIs is women.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05264103: Assessment of Robotic Assistance on Gait Parameters Among Healthy Subjects and Brain Damaged Patients
Official title: Assessment of Robotic Assistance on Gait Parameters.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2022-03-03
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main objective of this study is to quantitatively assess the robotic assistance given by an exoskeleton on patients gait parameters. Patients will be asked to walk with- and without the exoskeleton on a treadmill. During the study, the biomechanical and the energy consumption will be assessed.


Eligibility criteria: Inclusion Criteria:

* Hemiparesis due to stroke
* Min 18 years
* Time since stroke \> 15 days
* Ability to understand instructions
* Ability to do gait analysis on the treadmill

Exclusion Criteria:

- Contraindication for the use of the robot Atalante

Primary outcomes:
measure: Energy cost (J.kg/m)
timeFrame: 1 week
Secondary outcomes:
measure: Temporo-spatial parameters of gait: step length
timeFrame: 1 week
measure: Temporo-spatial parameters of gait: stance phase
timeFrame: 1 week
measure: Temporo-spatial parameters of gait: cadence
timeFrame: 1 week
measure: Segmental kinematics of gait (°)
timeFrame: 1 week
measure: Muscle activation
timeFrame: 1 week
measure: Mechanical work (J.kg/m)
timeFrame: 1 week
Other outcomes:
Locations:
city: Bruxelles
country: Belgium
facility: Cliniques universitaires Saint-Luc
Study officials:
affiliation: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
name: Thierry Lejeune
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03841903: Spinal Cord Analysis in Multiple Sclerosis
Official title: Structural Analysis of Spinal Cord Grey and White Matter Changes in Patients With Multiple Sclerosis: Sub-study Within the Swiss Multiple Sclerosis Cohort (SMSC-study)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Keywords: Spinal cord
Spinal cord atrophy
Cerebrospinal Fluid
Swiss Multiple Sclerosis Cohort
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2019-02-15
Enrollment: 79
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The recruitment of MS patients will take place within the ongoing SMSC study at the MS Clinic of the Department of Neurology (Neurologische Klinik und Poliklinik), University Hospital Basel (Universitätsspital Basel). Healthy subjects will be recruited by public announcements on the University Hospital's and the University's notice board.

Brief summary: Research project in which patients with Multiple Sclerosis (MS) are examined clinically and with magnetic resonance imaging (MRI). To evaluate spinal cord (SC) grey and white matter changes (incl. lesions) using fast, high-resolution MRI sequences with high contrast between SC and cerebrospinal fluid (CSF) as well as high contrast within the SC (grey-white matter contrast).

Detailed description: The Swiss Multiple Sclerosis Cohort (SMSC-Study) aims to better evaluate specific Multiple Sclerosis (MS) phenotypes through the systematic and standardised documentation and acquisition of clinical course and paraclinical tests such as magnetic resonance imaging (MRI), blood and cerebrospinal fluid (CSF) specimens.

Determination of the relative contribution of SC metrics (cervical cord volume, cervical grey matter (GM) cord volume, cervical white matter (WM) cord volume, SC lesion load) to disability in MS.

Eligibility criteria: Inclusion criteria

* Diagnosis of multiple sclerosis
* Steroid free period: \> 4 weeks
* healthy controls without any history of severe neurological, internistic or psychiatric disease

Exclusion Criteria for all participants:

* History of severe (other) neurological, internistic or psychiatric disease
* MRI related exclusion criteria:

  1. Paramagnetic and/or superparamagnetic foreign objects in the body
  2. Pacemaker
  3. Claustrophobia
  4. Pregnancy, lactation

Primary outcomes:
measure: Change in SC atrophy assessed by MRI
timeFrame: at baseline and after 1 year
Secondary outcomes:
measure: Change in Timed 25-foot walk test (T25-FW)
timeFrame: at baseline and after 1 year and after 5 years
measure: Change in Multiple Sclerosis Walking Scale-12 (MSWS-12) Questionnaire
timeFrame: at baseline and after 1 year and after 5 years
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Dep. of Neurology, University Hospital Basel
Study officials:
affiliation: Department of Neurology University Hospital Basel
name: Ludwig Kappos, Prof. Dr. MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04473703: Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients
Official title: A Prospective Study of Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in Non-Small Cell Lung Cancer Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Adverse Reactions
Immune Checkpoint Inhibitor
Non-Small Cell Lung Cancer Patients
Cardiac Event
Lead sponsor: Shanghai Chest Hospital
Sponsor class: OTHER
First posted: 2020-07-16
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 300 patients with primary non-small cell lung cancer treated with PD-1/PD-L1 immune checkpoint inhibitors(ICIs) are expected to included. And then the basic information and the examination results will be collected.

Brief summary: This is a prospective, open label, single arm study. A total of 300 patients with primary non-small cell lung cancer treated with PD-1/PD-L1 immune checkpoint inhibitors(ICIs) are expected to included . All patients will follow up for at least 1 year. Patients with cardiac adverse reactions after PD-1/PD-L1 immune checkpoint inhibitor treatment at admission or during the subsequently follow-up period will randomly assigned a random number to each patient by computer random sequence. Patients with odd random number will treat with RASI（renin-angiotensin system inhibitors）, and those with even random number will treat with ARNI（angiotensin-receptor-neprilysin inhibitor）.


Eligibility criteria: Inclusion Criteria:

1. Be willing and able to provide written informed consent/assent for the trial;
2. Lung cancer patients whose pathological results confirmed is primary non-small cell lung cancer, stage III\~IV;
3. Patients received with ICIs treatment, including anti-PD-1 or anti-PD-L1 for at least two courses;

Exclusion Criteria:

1. Patients who do not have pathological diagnosis;
2. Patients who can't finish the follow-up;
3. The anti-PD-1, anti-PD-L1 therapy was less than two courses;
4. Patients whose cancer diagnosed with small cell lung cancer.

Primary outcomes:
measure: Major Adverse Cardiovascular Events
timeFrame: 1 year
Secondary outcomes:
measure: Common Terminology Criteria for Adverse Events (CTCAE)
timeFrame: 1 year
measure: All cause of death
timeFrame: 1 year
measure: examination indexes
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03825003: Comparison of Joint Mobility Levels and Performance in Young Male Basketball Players and Sedentary Peers
Official title: Comparison of Joint Mobility Levels and Performance in Young Male Basketball Players and Sedentary Peers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypermobility, Joint
Keywords: Basketball
Sedentary
Joint Mobility
Performance
Lead sponsor: Biruni University
Sponsor class: OTHER
First posted: 2019-01-31
Enrollment: 80
Sex: MALE
Minimum age (years): 16
Maximum age (years): 22
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The e-picos website was used to calculate the sample size. We used correlation coefficient (r = 0.505) from Acar et al's study in tennis players according to flamingo test results. When 90% power for each group is determined as α = 0.05, sample size is determined as 37. Considering the possibility of drop out by 10 percent, the sample size was determined as 41. 41 basketball players and 41 sedentary peers were included in the study.

Brief summary: The aim of our study was to determine the joint mobility levels and its effects on performance in male basketball players and their sedentary peers aged 16-22 years.

According to the studies on the effect of hypermobility on the performance; The young athletes who played tennis had lower equilibrium results than those without hypermobility. Although there is not any study that investigate its effects in basketball, there are studies for tennis and volleyball in literature.


Eligibility criteria: Inclusion Criteria:

For Players:

* Being a healthy male between the ages of 16-22,
* Playing basketball for at least 1 year,
* Body Mass Index \<30,
* Volunteer to participate in research.

For Sedentary Peers:

* Being a healthy male between the ages of 16-22,
* International Physical Activity Questionnaire Short Form score \<600 MET-min/week,
* Body Mass Index \<30,
* Volunteer to participate in research.

Exclusion Criteria:

* To have a musculoskeletal problem which prevents the person from exercising,
* Having a cardiovascular system disorder that limits exercise capacity
* Neurological disorder or cognitive dysfunction
* Smoking

Primary outcomes:
measure: Beighton Score
timeFrame: 1 day
measure: Y-Balance Test
timeFrame: 1 day
measure: Flamingo Balance Test
timeFrame: 1 day
measure: Vertical Jump Test
timeFrame: 1 day
measure: T Drill Test
timeFrame: 1 day
Secondary outcomes:
measure: International Physical Activity Questionnaire-Short Form
timeFrame: 1 day
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Biruni University
Study officials:
affiliation: Biruni University
name: Begüm Kara Kaya, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03190603: Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis
Official title: Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Spondylarthropathies
Magnetic Resonance Imaging
Lead sponsor: Armed Forces Capital Hospital, Republic of Korea
Sponsor class: OTHER_GOV
First posted: 2017-06-19
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: Axial Spondyloarthritis (SpA) is a kind of inflammatory arthritis which includes ankylosing spondylitis. Common symptoms of axial SpA are inflammatory back pain, morning stiffness, peripheral arthritis, enthesitis. Controlling aforementioned symptoms are one of the goal in treatment, and another goal is preventing bony ankylosis of axial skeleton such as spine. Ankylosis can limit range of motion and lower the quality of life.

Non-steroidal antiinflammatory drug (NSAID) and Tumor necrosis factor (TNF)-a inhibitor are the current treatment options for axial SpA. These medications can improve pain and stiffness of axial SpA patients, however preventing bony ankylosis is not proven. Current study showed attenuating inflammation at early stage could prevent further bony destruction and ankylosis in axial SpA. Present study is designed to discover the therapeutic effect of NSAID whether NSAID could recover the early inflammatory bony change (bone marrow edema at MRI) and prevent further bony change.


Eligibility criteria: Inclusion Criteria:

1. 2009 Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis
2. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \> 4
3. definite bone marrow edema on Sacroiliac joint MRI

Exclusion Criteria:

1. Patients who have underling cancer / infectious disease / kidney disease / liver disease / cardiovascular or cerebrovascular disease
2. Patients who is using TNF-a inhibitor
3. Patients with side effects of NSAID
4. Patients with history of peptic ulcer
5. Patients who can't keep NSAID treatment

Primary outcomes:
measure: Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score of sacroiliac joint
timeFrame: Baseline, 6 weeks after, 12 weeks after
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Armed Forces Capital Hospital
Study officials:
References:
Clinical trial NCT06483503: Extra Wide Field of View Lens Study
Official title: A Prospective Cohort Study Evaluating a Novel Colonoscope With a 230-degree Extra-wide Field of View Optics (EFOV)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Colonic Polyp
Lead sponsor: Pentax Medical
Sponsor class: INDUSTRY
First posted: 2024-07-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults scheduled for screening colonoscopies, evaluation of a positive stool test or polyp surveillance colonoscopy.

Brief summary: The goal of this observation study is to learn about the feasibility of a new colonoscope which provides the physician an extra-wide field of view during a screening colonoscopy. The main question this study aims to answer is can this new type of colonoscope locate polyps during clinical use in patients.

Patients will undergo a routine colonoscopy for colorectal cancer or polyp surveillance and have one follow-up phone call up to 2 weeks of the colonoscopy.


Eligibility criteria: Inclusion Criteria:

* Screening for colorectal cancer at the age greater than or equal to 50 years, or evaluation of a positive stool test (i-FOBT) or polyp surveillance.
* Signed informed consent.

Exclusion Criteria:

* ASA classification ≥3.
* Age \<18 years.
* Known or suspicion of inflammatory bowel disease.
* Known polyp(s) for polypectomy.
* High risk for colorectal cancer, history of extensive polyposis, patients with known genetic disease.
* Prior colorectal surgery.
* Vulnerable subjects or subjects unable to follow the procedures of the investigation, e.g., due to language problems.
* Unable or unwilling to undergo bowel cleansing for colonoscopy.
* Female patients who are pregnant or nursing.
* Participation in another clinical trial within 30 days prior to the Screening Visit or during this study.

Primary outcomes:
measure: Cecal Intubation Rate
timeFrame: Day 1
Secondary outcomes:
measure: Procedure Time
timeFrame: Day 1
measure: Ileum Intubation Rate
timeFrame: Day 1
measure: Therapeutic Intervention Success Rate
timeFrame: Day 1
measure: Mean number of polyps per coloscopy and its detection rate
timeFrame: Day 1
measure: Mean number of adenomas and its detection rate
timeFrame: Day 14
measure: Mean number of sessile serrate lesions and its detection rate
timeFrame: Day 14
measure: Patient Satisfaction Survey
timeFrame: Day 14
Other outcomes:
Locations:
city: Düsseldorf
country: Germany
facility: RKM 740 Interdisciplinary Care Clinic - Gastroenterology
Study officials:
affiliation: RKM 740 Interdisciplinary Specialist Clinic
name: Horst Neuhaus, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00593203: Brain Tissue Specimen Collection
Official title: Molecular Neurosurgical Tissue Bank
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Brain Diseases
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
First posted: 2008-01-14
Enrollment: 2500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: infant through Adults

Brief summary: The Molecular Neurosurgical Tissue Bank will function as a tissue or specimen repository for biopsy specimens from patients (both adult and pediatric) undergoing brain surgery and brain procedures.

Detailed description: The Molecular Neurosurgical Tissue Bank will function as a tissue or specimen repository for biopsy specimens from patients (both adult and pediatric) undergoing brain surgery and brain procedures. Leftover tissue removed during the course of brain surgery will be collected and stored in neurosurgical laboratories for use in medical research that might be currently ongoing or for future research. In addition, blood and cerebral spinal fluid samples will also be collected and stored. Leftover cerebral spinal fluid (CSF) will be collected during standard of care procedures (lumbar punctures or ventricular drains) that take place at time of diagnosis, completion of therapy and relapse of disease or during neurosurgery. Blood will be drawn at time of routine lab draws required during the surgery or procedure.

Eligibility criteria: Inclusion Criteria:

* Subjects having any type of brain surgery, where a specimen will be collected.

Exclusion Criteria:

* none

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center, Deptartment of Neurological Surgery
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center, Department of Neurological Surgery
name: Reid C. Thompson, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06642103: Pain, Muscle Strength, Motor Imagery, Body Awareness on Function and Individuals With Chronic Lateral Epicondylitis
Official title: The Effect of Pain, Muscle Strength, Motor Imagery and Body Awareness on Function in Individuals With Chronic Lateral Epicondylitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lateral Epicondylitis
Lead sponsor: KTO Karatay University
Sponsor class: OTHER
First posted: 2024-10-15
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Lateral epicondylitis

Brief summary: The aim of this study was to examine the effect of muscle strength, pain, motor imagery and body awareness on function in individuals with lateral epicondylitis. The main question it aims to answer is: Do pain, motor imagery, muscle strength and body awareness have an impact on function in individuals with lateral epicondylitis?


Eligibility criteria: Inclusion Criteria:

* a diagnosis of chronic LET by a physician and
* a pain score \> 3 on a visual analog scale (VAS).

Exclusion Criteria:

* concomitant disorders of the wrist and forearm, such as elbow fracture or dislocation, and treatment with corticosteroid injections within the previous 6 months

Primary outcomes:
measure: Function
timeFrame: baseline
Secondary outcomes:
measure: Pain severity
timeFrame: Baseline
measure: Motor imagery
timeFrame: Baseline
measure: Grip strength
timeFrame: Baseline
measure: The Body Awareness
timeFrame: Baseline
Other outcomes:
Locations:
city: Konya
country: Turkey
facility: KTO Karatay University
state: Karatay
Study officials:
References: